SCHEMBL5763657

SCHEMBL5763657

Cc1cc(NC(=O)CCl)c2nc(C)n(-c3ccc(Cl)cc3Cl)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HTT P42858 3/20 0.44
JAK2 O60674 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 3/20 0.40
MAPT P10636 1/20 0.40
CRHR1 P34998 2/20 0.39
CD38 P28907 2/20 0.39
HPGD P15428 2/20 0.39
NOTUM Q6P988 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
CNR1 P21554 2/20 0.37
CNR2 P34972 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762572 0.83 CRHR1 (0.40) RAB9ACRHR1CD38NOTUMCYP2C9
SCHEMBL5763836 0.79 ALDH1A1 (0.45) LMNASMN1; SMN2ALDH1A1HTTTP53
SCHEMBL5764592 0.75 NPY1R (0.47) SMN1; SMN2CRHR1HPGDCNR1CNR2
SCHEMBL5765581 0.74 NR4A2 (0.43) ALDH1A1RAB9AKDM4EMAPTCRHR1
SCHEMBL5762383 0.73 MEN1 (0.47) LMNASMN1; SMN2ALDH1A1HTTTP53
SCHEMBL29678338 0.68 HPGD (0.62) LMNASMN1; SMN2ALDH1A1HTTRAB9A
SCHEMBL5858216 0.68 HPGD (0.62) LMNASMN1; SMN2ALDH1A1HTTRAB9A
SCHEMBL10603640 0.66 ALDH1A1 (0.73) LMNASMN1; SMN2ALDH1A1HTTRAB9A
SCHEMBL29528302 0.66 ALDH1A1 (0.73) LMNASMN1; SMN2ALDH1A1HTTRAB9A
SCHEMBL4005240 0.66 GAA (0.71) LMNASMN1; SMN2ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
EP-1224187-B1 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORP (US) 2006-02-22 EP disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R LMNA 2161/4885SMN1; SMN2 2884/4885ALDH1A1 4696/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R LMNA 2274/4885SMN1; SMN2 2941/4885ALDH1A1 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.